Nachrichten zur Intellia Therapeutics Aktie

3 Things You Need to Know if You Buy CRISPR Therapeutics Today

CRISPR Therapeutics (NASDAQ: CRSP) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential…

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?

Shares of biotech Intellia Therapeutics (NASDAQ: NTLA) are down by around 33% over the past 30 days, amid the publication…

Intellia Therapeutics Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)

…

Gen-Schere Hoffnungsträger Intellia Therapeutics: Aktie mit Kurssprung – die Hintergründe

Das Gros der Biotech- und Pharmawerte hat in den vergangenen Tagen nach der Ankündigung Donald Trumps, Robert F. Kennedy Jr.…

Gen-Schere Hoffnungsträger Intellia Therapeutics: Aktie mit Kurssprung – die Hintergründe

Das Gros der Biotech- und Pharmawerte hat in den vergangenen Tagen nach der Ankündigung Donald Trumps, Robert F. Kennedy Jr.…

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus

…

Intellia Therapeutics, Inc. (NTLA) Q3 2024 Earnings Call Transcript

…

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? @themotleyfool #stocks $NTLA

Theres nothing bearish at all about what it reported recently.…

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?

Theres nothing bearish at all about what it reported recently.…

Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity

…

Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study By Investing.com

Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study…

This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street @themotleyfool #stocks $NTLA

Intellia Therapeutics innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.…

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

[Latest] Global Genetic Engineering Market Size/Share Worth USD 2,917.2 Million by 2033 at a 6.74% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Therapeutics Announces CFO Transition

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

CAMBRIDGE, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Therapeutics: "buy"

Charlotte, NC (www.aktiencheck.de) - Rating-Update: Die Analysten von Truist stufen die Aktie von Intellia Therapeutics Inc. (ISIN: US45826J1051, WKN: A2AG6H, Ticker-Symbol:…

Global Genome Editing Market Size To Worth USD 34.75 Billion By 2033 | CAGR Of 16.19%

The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023 and the Worldwide Genome Editing Market…

Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies

…

Earnings call: Intellia Therapeutics reports robust Q1 progress By Investing.com

Earnings call: Intellia Therapeutics reports robust Q1 progress…

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Is Intellia Therapeutics Stock a Buy Now?

The companys future will depend on its innovative qualities.…

Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst

2024 could see the start of its first late-stage clinical trials.…

Intellia Therapeutics, Inc. (NTLA) Q4 2023 Earnings Call Transcript

…

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics

Both companies are going to continue doing high-impact science in 2024.…

Biotech Market Forecast: Top Trends That Will Affect Biotech in 2024

The biotech sector is a dynamic and constantly evolving industry that is driving scientific advancements and innovation in healthcare. According…

Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics

These two are at very different stages of the clinical trials process.…

Intellia Therapeutics files for mixed shelf

…

Genome Editing Market revenue to hit USD 69.6 Billion by 2036, says Research Nester

Leading genome editing market players include Merck KGaA, Horizon Discovery Ltd., Lonza Group Ltd., Twist Bioscience Corporation, Akron Biotech., CRISPR…

Intellia Therapeutics, Inc. (NTLA) Q3 2023 Earnings Call Transcript

…

Intellia Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company…

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Intellia Therapeutics,…

dpa-AFX ProFeed